TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of directors (the “Board”). Effective today, Mr. Eyal Gabbai has been appointed to the Board replacing Dr. Gadi Riesenfeld, who has resigned from the Board. Dr. Riesenfeld will continue to support NurExone as a member of the Company’s Scientific Advisory Board.
The Company believes Mr. Gabbai’s experience in healthcare leadership, capital markets, and with global investors will be valuable as NurExone advances its preclinical programs toward first-in-human milestones and evaluates potential future capital markets opportunities, subject to market conditions and regulatory requirements.
“This appointment reflects our focus on engaging with partners who understand both patient needs and the economics of healthcare,” said Yoram Drucker, Chairman of NurExone. “Eyal brings deep experience across healthcare systems, technology adoption, market implementation, as well as a strong understanding of public company and regulated environments. His perspective will be valuable as we continue to build NurExone’s platform and engage with global partners, public-market stakeholders, and investors.”
“I chose to join NurExone because of the strength of its technology and science and the disciplined way the team is approaching development in an area of medicine where current solutions are not good enough,” said Eyal Gabbai. “Exosome-based therapies hold significant potential, and NurExone is advancing this field with a clear focus on data and execution. I also value the Company’s dual outlook, pursuing nearer term opportunities through exosome supply and collaborations, while building longer term potential through advancing proprietary drug candidates.”
Mr. Gabbai brings extensive healthcare and international capital markets experience. He is currently Chairman of Meuhedet Health Fund, Israel’s third largest health maintenance organization, with approximately 1.4 million members and annual turnover exceeding US$3 billion. He is also Chairman of Medica Excel, a private hospital network. He previously served as Director-General of Israel’s Prime Minister’s Office, overseeing policy coordination across infrastructure, capital markets, communications and housing, with engagement across government, international counterparts, and the private sector. From 2002 to 2007, he was Director General of Israel’s Government Companies Authority, leading major privatization and capital markets transactions with aggregate proceeds exceeding US$5 billion through initial public offerings and strategic sales.
The Company thanks Dr. Riesenfeld for his service and meaningful contributions to the Board during a formative period in which NurExone advanced its regenerative medicine platform and expanded its global engagement.
About NurExone
NurExone is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: Dr. Riesenfeld continuing to support the Company; expected benefits from the appointment of Mr. Gabbai, including anticipated improvements in capital markets readiness and international engagement; the Company’s development plans, including advancing ExoPTEN toward first‑in‑human clinical trials; expected optimization of manufacturing processes and analytical methods; anticipated regulatory submissions; the potential capabilities and applications of the Company’s exosome‑based drug delivery technologies; and the Company’s intentions regarding partnerships, collaborations, and expansion of investor and partner engagement.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company’s ability to execute its development plans; the continued availability of capital and access to required expertise; the performance of preclinical models; the Company’s ability to prepare and submit regulatory filings within anticipated timelines; and the continued applicability and scalability of its exosome production and delivery platforms.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: uncertainties inherent in early‑stage biotechnology development; risks associated with research, preclinical studies and clinical trials; regulatory risks, including the timing and outcome of regulatory submissions; manufacturing and scale‑up risks; reliance on third‑party partners; competition from alternative technologies; market adoption risks; intellectual property risks; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. The forward‑looking information in this press release is made as of the date hereof, and the Company undertakes no obligation to update or revise any forward‑looking information, except as required by applicable law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
i Spinal cord injury, Glaucoma
